Roy Fleischmann, MD

Metroplex Clinical Research Center and University of Texas Southwestern Medical Center
Dallas, TX, United States

Roy Fleischmann is Clinical Professor of Medicine at the University of Texas Southwestern Medical Center and Medical Director of the Metroplex Clinical Research Center in Dallas, Texas, USA. He received his MD from the State University of New York, Downstate Medical Center, and completed his residency in medicine at Mount Sinai Medical Center in New York City. His fellowship in rheumatology was completed at the College of Physicians and Surgeons of Columbia University, New York. He was elected a Master of the American College of Rheumatology (ACR) in 2010.
Professor Fleischmann has authored over 250 manuscripts and more than 450 abstracts, focusing on the management of rheumatoid arthritis, which have been published in leading international peer-reviewed journals, and presented at prestigious rheumatology meetings worldwide. With more than 40 years of experience as a clinical investigator, Professor Fleischmann has been a principal or co-principal investigator in over 1,000 clinical studies in the field of rheumatology. He has presented frequently at the ACR and EULAR Annual Meetings and is Editor of Rheumatology and Therapy and on the Editorial Board of the Annals of Rheumatic Disease, RMDOPen, Journal of Rheumatology and Expert Opinion on Drug Safety. He has served as a reviewer for many peer-reviewed journals including Arthritis & Rheumatism, Annals of Rheumatic Disease, Lancet, the New England Journal of Medicine and the Journal of Rheumatology

Disclosure information not submitted.

Presentation(s):

• 0282: Efficacy and Safety of Upadacitinib in TNFi-IR Patients with Rheumatoid Arthritis from Three Phase 3 Clinical Trials

  Saturday, November 12, 2022
  1:00 PM – 3:00 PM Eastern Time

• 0294: Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis and Inadequate Response or Intolerance to Biologic DMARDs: Results Through 5 Years from the SELECT-BEYOND Study

  Saturday, November 12, 2022
  1:00 PM – 3:00 PM Eastern Time

• 1589: Multiple Switching Between the Biosimilar Adalimumab PF-06410293 (Abrilada™) and Reference Adalimumab (Humira®)in Combination with Methotrexate in Patients with Moderately to Severely Active Rheumatoid Arthritis

  Sunday, November 13, 2022
  4:00 PM – 4:10 PM Eastern Time

• 245: Navigating the PATH to Managing Rheumatoid Arthritis

  Monday, November 14, 2022
  11:30 AM – 12:15 PM Eastern Time

• 2132: Safety of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor: As Assessed by Laboratory Parameters – Results from a Phase 2 Trial in Psoriatic Arthritis and 2 Phase 3 Trials in Psoriasis

  Monday, November 14, 2022
  1:00 PM – 3:00 PM Eastern Time